cruzi

T.cruzi-IN-1 (MDK1088) is a Trypanosoma cruzi inhibitor.

ML251 is a potent novel nanomolar inhibitor of T. brucei and T. cruzi phosphofructokinase[1]. ML251 inhibits T. brucei PFK (IC50=0.37 μM) and T. cruzi PFK (IC50=0.13 μM). ML251 can be used for the research of parasite[1].

Anti-Trypanosoma cruzi agent-6 (Compound 8) exhibits inhibitory activity against Trypanosoma cruzi. It effectively suppresses the epimastigote, trypomastigote, and amastigote forms of T. cruzi, with IC50 values of 24.7 µM, 1.8 µM, and 1.6 µM, respectively.

Anti-Trypanosoma cruzi agent-7 (compound 1) is a potent Trypanosoma cruzi inhibitor with an EC50 of 1.26 µM. This compound is used in the study of Chagas disease.

Anti-Trypanosoma cruzi agent-1 (Compd 3b), a selective compound against NINOA trypomastigote (IC 50 = 0.51 μM) and INC-5 epimastigote (IC 50 = 3.06 μM), also possesses anti-T. gondii activity [1].

Anti-Trypanosoma cruzi agent-1 (Compd E5) demonstrates a potent anti-Toxoplasma effect.

Anti-Trypanosoma cruzi agent-3 is an antiprotozoal agent.

Anti-Trypanosoma cruzi Agent-4 is a Trypanosoma cruzi inhibitor utilized for the investigation of infections caused by this parasite.

T.cruzi Inhibitor hydrochloride is a Trypanosoma cruzi inhibitor.

T.cruzi-IN-4 (Compound 21) is an antiparasitic agent. It suppresses both the trypomastigote and amastigote forms of Trypanosoma cruzi, achieving an IC50 of 0.033 μM (after 120 hours). Additionally, T.cruzi-IN-4 hinders the promastigote and amastigote forms of Leishmania infantum, with IC50 values of 28.74 and 61.82 μM respectively, and it inhibits the promastigote form of Leishmania amazonensis with an IC50 of 18.38 μM.

K777 is a potent, orally active, and irreversible inhibitor of cysteine protease, functioning as a potent CYP3A4 inhibitor (IC50 = 60 nM) and a selective CCR4 antagonist, which inhibits chemotaxis. K777 irreversibly inhibits Cruzain, the major cysteine protease of Trypanosoma cruzi, and cathepsins B and L, targeting cathepsin-mediated cell entry and exhibiting broad-spectrum antiviral activity. It inhibits EBOV and SARS-CoV pseudovirus entry with IC50 values of 0.87 nM and 0.68 nM, respectively.

Moxipraquine is a novel 8-aminoquinolone compound with anti-infective activity against Trypanosoma cruzi. Moxipraquine effectively inhibited parasitemia but did not eradicate infections in mice or guinea pigs. Moxipraquine was effective against experimental infections of Leishmania major, Lactobacillus mexicanus, and Lactobacillus brasiliensis, but was Ineffective.

Nifurtimox (BAY-A-2502) is an antiprotozoal agent (IC50s = 9.91, 12.28, and 10.44 μM against Taluahuén, LQ, and Brener strains of T. cruzi- epimastigotes, respectively).

Diloxanide furoate (Dichlofurazol) is an antiprotozoal compound with oral activity that can be used in the study of amoebas in tissues and several other protozoal infections.

TcNTPDase1-IN-1 (compound 16) serves as an inhibitor of nucleoside triphosphate diphosphohydrolase 1 (TcNTPDase1) from Trypanosoma cruzi in vitro. This compound is applicable in research related to antibacterial, antitoxic, and antitumor activities.

VNI is an effective inhibitor of CYP51. It suppresses sterol synthesis in Trypanosoma cruzi, exhibiting anti-Trypanosoma cruzi activity.

Se2h is a cruzain inhibitor exhibiting potent activity against intracellular amastigotes of Trypanosoma cruzi (EC50< 1 μM, SI> 10), with an inhibitory effect on cruzain of IC50< 100 nM (SI> 5.55). Compared to Benznidazole and cruzain inhibitor K777, Se2h shows superior selectivity and inhibition while its selenazole structure reduces selenium-related toxicity. Se2h demonstrates antiparasitic activity and holds promise for Chagas disease research.

MCG-02 is an inhibitor of cruzain (CRZ) and cathepsin L-like protease (CATL), capable of inhibiting CRZ in Trypanosoma cruzi and CATL in Trypanosoma brucei, with IC50 values of 0.2 μM and 0.02 μM, respectively.

PFK-IN-1 (compound 1) is an inhibitor of 6-phosphofructo-1-kinase (PFK), demonstrating IC50 values of 0.41 and 0.23 μM against T. brucei and T. cruzi PFK, respectively, and an ED50 of 15.18 μg mL for T. brucei. The compound has a half-life of 9.7 minutes in rat liver microsomes and 408 minutes in mouse liver microsomes.

TSO-13 is an inhibitor of the major cysteine protease Cruzipain found in Trypanosoma cruzi, with an IC50 of 2.2 μM. In Vero cells, TSO-13 also suppresses T. cruzi, exhibiting an IC50 of 1.9 μM.

Antiparasitic agent-24 (Compound 14a) is an antiparasitic compound with EC50 values of 0.005 μM for L. maj, 0.069 μM for L. don, 0.82 μM for T. brucei, and 4.1 μM for T. cruzi.

CZP-IN-1 (compound SH-1) is an inhibitor targeting the pathogen Trypanosoma cruzi protease (CZP) without affecting cathepsin L (IC50=28 nM). This compound is applicable in Chagas disease research.

POPTc80-IN-1 (Compound LC-45) is a competitive inhibitor of Trypanosoma cruzi prolyl oligopeptidase (POPTc80), with an IC50 of 0.23 μM and a Ki of 0.054 μM. It inhibits the invasion of host cells by T. cruzi, with an IC50 of 46.71 μM.

Antitrypanosomal agent 23 is an antiparasitic compound effective against intracellular amastigotes of Trypanosoma cruzi in LLC-MK2 and C2C12 cells, demonstrating activity with IC50 values of 0.10 and 0.11 μM, respectively. It also acts as a weak inhibitor of recombinant Trypanosoma cruzi sialyltransferase (TcTS) with an IC50 of 1.1 mM.